Metabolic Steatotic Liver Disease

Dr. Nguyen is Professor of Medicine and Director for the Hepatology Fellowship in the Division of Gastroenterology and Hepatology and Liver Transplant Program and by courtesy Professor of Epidemiology and Population Health at Stanford University Medical Center and Director for the Hepatology Clerkship for Stanford University School of Medicine. She is also a member of the Stanford Cancer Institute, Stanford Bio-X and Stanford Population Science. She has served as a member of the Appointment and Promotion Committee for the Department of Medicine as well as a Diversity LENS Advocate for the Department. She is both clinically active and does research with single-center Stanford-based cohorts, multi-center Bay Area consortium, multi-center US consortia as well as international cohorts. She is a Fellow of the American Association for the Study of Liver Diseases and the American Gastroenterological Association, as well as member of the American College of Gastroenterology, European Association for the Study of Liver Diseases and the Asia Pacific Association for the Study of Liver Diseases. Linda Henry is an academic researcher from Stanford University. The author has contributed to research in topic(s): Hepatitis C & Sofosbuvir. The author has an hindex of 42, co-authored 197 publication(s) receiving 12359 citation(s). Previous affiliations of Linda Henry include Inova Health System & University of Florida.

1. Global Epidemiology of NAFLD (now and forecasted)
2. U.S. Epidemiology of NAFLD (now and forecasted). Linda Henry, PhD; Stanford University, USA
3. Economic and patient reported outcome burden (now and forecasted)
4. NAFLD pathogenesis (environmental and genetic)
5. Clinical presentation and natural history.6. Non-liver comorbidities (prevalence and incidence)
7. Screening, diagnosis, and evaluation of patients with NALFD
8. Non-invasive evaluation of liver fibrosis (serum-based)
9. Non-invasive evaluation of liver fibrosis (imaging/elastography-based)
10. General treatment principles
11. Non-surgical treatment of obesity and metabolic disease
12. Endoscopic and surgical treatment of obesity
13. Pharmacologic treatment of hepatic steatosis
14. Overview and comparison of current guidelines (AASLD, EASL, APASL) on NAFLD and MAFLD controversies
15. Special populations: Fatty liver disease in children and adolescent and in the presence of other liver diseases
16. Special populations: Fatty liver disease in patients with chronic hepatitis